ZSZhengyao Shao

Zhengyao Shao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhengyao Shao has a total of 107 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Qiao

    Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, TX 78712, USA; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712, USA

    9 shared publications
  • Yan-Ruide Li

    Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles

    4 shared publications
  • Bo Zhao

    Institute for Cellular and Molecular Biology The University of Texas at Austin Austin TX 78712 USA

    3 shared publications
  • Haochen Nan

    Department of Bioengineering, University of California Los Angeles, Los Angeles, CA, USA

    3 shared publications
  • Likai Wang

    State Key Laboratory of Crop Genetics and Germplasm Enhancement and Utilization; Key Laboratory of Flower Biology and Germplasm Innovation, Ministry of Agriculture and Rural Affairs; College of Horticulture, Nanjing Agricultural University , Nanjing 210095

    3 shared publications
  • Song Li

    Department of Bioengineering, University of California Los Angeles, Los Angeles, USA

    3 shared publications

Latest Publications

  • Open Access

    Engineered stem cell-derived CD16-enhanced universal NKT cells improve monoclonal antibody-based cancer immunotherapy

    by Yan-Ruide Li, Yichen Zhu, Yanqi Yu, Adam Kramer, Zhengyao Shao, Yuning Chen, Xinyuan Shen, Catherine Zhang, Nathan Ma, Annabel Zhao, et al.

    Monoclonal antibody (mAb)-based therapies have revolutionized cancer treatment; however, their clinical efficacy is often limited by insufficient antibody-dependent cellular cytotoxicity (ADCC), tumor antigen escape, and an immunosuppressive tumor microenvironment (TME). To overcome these limitations, we developed an allogeneic stem cell-derived invariant natural killer T (NKT) cell platform engineered to express a high-affinity non-cleavable CD16 receptor (CD16HSC-NKT) for broad enhancement of mAb-based immunotherapy. Using a clinically guided differentiation platform, we generated highly pure and scalable CD16HSC-NKT cells exhibiting robust expression of NK receptors, potent cytotoxic machinery, and a Th1-biased cytokine profile. CD16HSC-NKT cells demonstrated potent intrinsic antitumor activity and potently enhanced the efficacy of multiple therapeutic antibodies, including Trastuzumab, Tafasitamab, Rituximab, Daratumumab, and Cusatuzumab, across diverse hematologic and solid tumor models. In vivo, combination therapy induced durable tumor eradication and prolonged survival in xenograft models, outperforming the clinically approved antibody-drug conjugate trastuzumab deruxtecan. Mechanistically, therapeutic antibodies promoted the expansion, persistence, and activation of CD16HSC-NKT cells within tumors. CD16HSC-NKT uniquely remodeled the TME by selectively depleting CD1d-expressing tumor-associated macrophages and myeloid-derived suppressor cells. CD16HSC-NKT cells also exhibited minimal alloreactivity, no graft-versus-host disease, and no detectable systemic toxicity. Collectively, these findings establish CD16HSC-NKT cells as a safe, off-the-shelf cellular platform capable of broadly enhancing monoclonal antibody therapy through sustained ADCC, multimodal tumor targeting, and TME remodeling.

  • Open Access

    Metabolic Competition Reshapes the Performance of Engineered Polyketide Synthases

    by Yu Zhou, Zhengyao Shao, Xueyi Xue, Li-Qing Chen, Hong Qiao, Yi Lu

    Directed evolution is widely used to enhance enzymatic performance and evolve new-to-nature reactivities, typically in vitro or in model microbial systems. However, variants selected in a model host may not retain their relative performance in the intended production organism. Here, we engineered a single 2-pyrone synthase (2PS) scaffold by directed evolution in Escherichia coli ( E. coli ) and evaluated the resulting variants in both E. coli and planta. In E. coli, engineered 2PS variants showed distinct chemoselectivities, giving access to precursors for kavalactones and raspberry ketone from one protein scaffold. The best variant achieved >98% conversion of p -coumaric acid to >200 µg/mL bisnoryangonin. In planta, however, variant performance was reordered: the top-performing microbial variant was outperformed 2.7-fold by one with lower activity in E. coli . We traced this host-dependent shift to competition for the shared p -coumaroyl-CoA pool and identified cinnamoyl-CoA reductase from Nicotiana benthamiana ( Nb CCR) as a key competing enzyme. Introducing Nb CCR into E. coli recapitulated the variant rank order observed in planta, demonstrating that metabolic competition can reshape the performance of engineered enzymes across hosts. These results also suggest that reconstructing key competing pathways of the target host in a tractable microbial system can provide a practical strategy for engineering enzymes for otherwise difficult-to-evolve production hosts. Finally, 2PS variants enabled the chemoenzymatic synthesis of natural and fluorinated kavalactones with up to 64% isolated yield over two steps.

  • Open Access

    Metabolic Competition Reshapes the Performance of Engineered Polyketide Synthases

    by Yu Zhou, Zhengyao Shao, Xueyi Xue, Li-Qing Chen, Hong Qiao, Yi Lu

    Directed evolution is widely used to enhance enzymatic performance and evolve new-to-nature reactivities, typically in vitro or in model microbial systems. However, variants selected in a model host may not retain their relative performance in the intended production organism. Here, we engineered a single 2-pyrone synthase (2PS) scaffold by directed evolution in Escherichia coli ( E. coli ) and evaluated the resulting variants in both E. coli and planta. In E. coli, engineered 2PS variants showed distinct chemoselectivities, giving access to precursors for kavalactones and raspberry ketone from one protein scaffold. The best variant achieved >98% conversion of p -coumaric acid to >200 µg/mL bisnoryangonin. In planta, however, variant performance was reordered: the top-performing microbial variant was outperformed 2.7-fold by one with lower activity in E. coli . We traced this host-dependent shift to competition for the shared p -coumaroyl-CoA pool and identified cinnamoyl-CoA reductase from Nicotiana benthamiana ( Nb CCR) as a key competing enzyme. Introducing Nb CCR into E. coli recapitulated the variant rank order observed in planta, demonstrating that metabolic competition can reshape the performance of engineered enzymes across hosts. These results also suggest that reconstructing key competing pathways of the target host in a tractable microbial system can provide a practical strategy for engineering enzymes for otherwise difficult-to-evolve production hosts. Finally, 2PS variants enabled the chemoenzymatic synthesis of natural and fluorinated kavalactones with up to 64% isolated yield over two steps.

  • Open Access

    Genetically targeted mTORC1 inhibitor reveals transcriptional control by nuclear mTORC1

    by Yanghao Zhong, Ayse Z. Sahan, Zhengyao Shao, Qian-Yi Zhang, Xin Zhou, Jack G. Haggett, Keiichi Koshizuka, Samuel A. Myers, J. Silvio Gutkind, Jin Zhang

    Mechanistic target of rapamycin complex 1 (mTORC1) is a nutrient sensor that integrates diverse inputs to regulate protein translation and cell growth. While mTORC1 is activated on the lysosome in the classical model, it has become increasingly clear that this multifaceted signaling complex is active at various subcellular locations, such as the nucleus. However, what specific functions mTORC1 serves at these locations and how its signaling is compartmentalized are unclear. To interrogate subcellular pools of mTORC1, we developed TerminaTOR, a genetically encodable inhibitor of mTORC1 that can be targeted to specific subcellular locations. When TerminaTOR is directed to the lysosome, it inhibits canonical lysosomal mTORC1 and induces autophagy. Furthermore, TerminaTOR targeted to the nucleus specifically inhibits nuclear mTORC1, uncovering noncanonical roles of nuclear mTORC1 in regulating the transcription of CCAAT motif-containing genes. Thus, mTORC1 exhibits functional spatial compartmentalization and TerminaTOR serves as a powerful tool for unraveling spatially regulated functions of mTORC1 across different scales.


  • Spongy mesophyll cell death is induced by jasmonic acid during leaf senescence in chrysanthemum

    by Jing Song, Yuming Zhang, Xiaoyue Hu, Zhengyao Shao, Aiping Song, Jiafu Jiang, Sumei Chen, Fadi Chen, Likai Wang

    Leaf senescence impacts crop yield, quality, and post-harvest performance; for example leaf senescence limits the shelf life of cut flowers. Although the senescence process has been extensively studied at the whole-leaf level, its regulation at the single-cell-type level remains largely unknown. Here, we tracked the cell death process during leaf senescence at the single-cell-type resolution through integrated anatomical, multiomics, molecular and genetic analyses in chrysanthemum (Chrysanthemum morifolium Ramat.). These analyses revealed that jasmonic acid (JA) induces spongy mesophyll cell death in the initial stage of leaf senescence, mediated by the transcription factors CmNAC055 and CmNAC087. These transcription factors regulate the acyl coenzyme A oxidase gene CmACX5, encoding a key JA biosynthetic enzyme. This regulatory module is functionally conserved across diverse species, including chrysanthemum, Arabidopsis thaliana, tomato (Solanum lycopersicum), and rice (Oryza sativa). Indeed, attenuating mesophyll cell death with a JA biosynthesis inhibitor delays tomato fruit de-greening and increases rice grain yield by approximately 6%. This study establishes a dynamic landscape of cell fate determination and hormonal regulation during leaf senescence, providing strategies to increase plant production by modulating leaf senescence.


  • Top Cited Papers

    Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

    by Yan-Ruide Li, Haochen Nan, Zeyang Liu, Ying Fang, Yichen Zhu, Zibai Lyu, Zhengyao Shao, Enbo Zhu, Bo Zhang, Youcheng Yang, et al.

    Invariant natural killer T (iNKT) cells are a unique subset of T lymphocytes with allogeneic potential and strong solid tumour-homing capacity, making them attractive for cancer immunotherapy. Unlike conventional T cells, iNKT cells recognize lipid antigens presented by the non-polymorphic CD1d molecule. Chimaeric antigen receptor (CAR)-redirected iNKT (CAR-iNKT) cells have shown promise; however, their clinical efficacy is limited by insufficient activation and poor long-term persistence within the tumour microenvironment. Here we describe the iNKT cell-targeted microparticle recruitment and activation system (iMRAS), a biomimetic platform engineered to locally recruit, activate and expand CAR-iNKT cells in vivo. Acting as an in vivo 'charging station', iMRAS provides chemotactic and activating cues that enhance CAR-iNKT cell functionality, improving persistence and tumour control in preclinical lymphoma and melanoma models. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumours, establishing a robust platform for advancing CAR-iNKT cell-based cancer immunotherapy.


  • Open Access

    Stem cell mitochondrial transfer rejuvenates CAR-NKT cell metabolism and antitumor activity

    by Yan-Ruide Li, Bo Zhang, Shubing Wang, Yichen Zhu, Xinyuan Shen, Zhengyao Shao, Yuning Chen, Jie Huang, Haochen Nan, Youcheng Yang, et al.

    Chimeric antigen receptor–engineered natural killer T (CAR-NKT) cells have emerged as a promising cancer immunotherapy owing to their potent antitumor activity, efficient tissue homing, and capacity to remodel the immunosuppressive tumor microenvironment (TME). Although strategies such as cytokine engineering and checkpoint blockade have improved CAR-NKT cell function, approaches that enhance their metabolic fitness remain limited. Here, we rejuvenate CAR-NKT cell metabolism and antitumor activity through induced pluripotent stem cell–derived mitochondrial transfer (iPSC-MT). iPSC-MT markedly enhances mitochondrial activity and metabolic fitness in CAR-NKT cells, resulting in improved effector function, memory formation, and persistence while limiting exhaustion. CAR-NKT cells enhanced by iPSC-MT (CAR-NKTMito) exhibit superior cytotoxicity in vitro and robust antitumor efficacy in vivo across multiple xenograft mouse models, including human lymphoma, liver cancer, and ovarian cancer. Notably, CAR-NKTMito cells exhibit enhanced TME modulation through effective targeting of CD1d⁺ myeloid cells, outperforming conventional iPSC-MT-enhanced CAR-T cells. Together, these findings establish mitochondrial transfer as a powerful organelle-level metabolic reprogramming strategy to enhance CAR-NKT cell function and provide a new therapeutic paradigm for improving cellular immunotherapy against cancer.


  • Open Access

    Competition Binding of CmbHLH1L and CmNLP6 / 7L to CmbHLH63 Modulates Leaf Senescence in Chrysanthemum

    by Yuna Yang, Ziyan Qian, Yinglin Li, Rui Liu, Hong Qiao, Zhengyao Shao, Debao Huang, Jiafu Jiang, Fadi Chen, Sumei Chen, et al.

    Leaf senescence impacts the quality, productivity and post‐harvest performance of crops and ornamental plants. However, the underlying molecular mechanisms governing this process remain poorly understood. In this study, we identified CmbHLH63 as a ‘brake signal’ of leaf senescence in chrysanthemum and elucidated its critical regulatory role within the CmbHLH1L‐CmbHLH63‐CmNLP6/7L complex. CmbHLH63 promotes leaf senescence, while it is downregulated during this process. Notably, CmbHLH63 lacks intrinsic transcriptional regulatory activity; however, the expression of a majority of genes was repressed in plants overexpressing CmbHLH63 . Further investigation revealed that this repression is achieved through recruiting the transcriptional repressor CmbHLH1L. We further found that CmNLP6/7L, a transcriptional activator, competes with CmbHLH1L for the interaction with CmbHLH63, leading to the release of their inhibition on downstream gene CmNLP6/7L . We found that the accumulation of CmbHLH1L is increased in the cytoplasm and decreased in the nucleus during leaf senescence. Mass spectrometry assays and subcellular localization studies revealed that CmbHLH1L undergoes lysine acetylation at position 140, which prevents its nuclear accumulation, thereby elevating CmNLP6/7L expression during leaf senescence.


  • Open Access

    Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy

    by Song Li, Yan-Ruide Li, Haochen Nan, Zeyang Liu, Ying Fang, Yichen Zhu, Zibai Lyu, Zhengyao Shao, Enbo Zhu, Bo Zhang, et al.

    Invariant natural killer T (iNKT) cells are a distinct subset of T lymphocytes that possess unique properties making them highly suitable for addressing the challenges of solid tumor immunotherapy. Unlike conventional T cells, which are restricted by polymorphic major histocompatibility complex (MHC) molecules and recognize peptide antigens, iNKT cells are restricted by the non-polymorphic CD1d molecule and respond to lipid antigens. Chimeric antigen receptor (CAR)-redirected iNKT (CAR-iNKT) cells represent a significant advancement in cancer immunotherapy. However, optimizing sustained activation and long-term persistence of CAR-iNKT cells remains a critical need for effective solid tumor treatment. To address these limitations, we develop the iNKT cell-targeted microparticle recruitment and activation system (iMRAS), a biomimetic platform designed to enhance iNKT cell functionality through localized immunostimulation in vivo. This biomimetic platform is designed to function as an in vivo “charging station” containing chemotactic and activation signals for the recruitment, activation, and expansion of CAR-iNKT cells, leading to more effective tumor killing and longer persistence of CAR-iNKT cells, as demonstrated in the therapy of lymphoma and melanoma. Through its biomimetic design and localized immunostimulatory effects, iMRAS helps overcome the limitations of current therapies for solid tumors, establishing a robust platform for enhancing systemic CAR-iNKT cell-mediated immunotherapy.


  • Open Access

    Nuclear pyruvate dehydrogenase complex regulates histone acetylation and transcriptional regulation in the ethylene response

    by Zhengyao Shao, Liangqiao Bian, Shyon K. Ahmadi, Tyler J. Daniel, Miguel A. Belmonte, Jackson G. Burns, Prashanth Kotla, Yang Bi, Zhouxin Shen, Shou-Ling Xu, et al.

    Ethylene plays its essential roles in plant development, growth, and defense responses by controlling the transcriptional reprograming, in which EIN2-C–directed regulation of histone acetylation is the first key step for chromatin to perceive ethylene signaling. But how the nuclear acetyl coenzyme A (acetyl CoA) is produced to ensure the ethylene-mediated histone acetylation is unknown. Here we report that ethylene triggers the accumulation of the pyruvate dehydrogenase complex (PDC) in the nucleus to synthesize nuclear acetyl CoA to regulate ethylene response. PDC is identified as an EIN2-C nuclear partner, and ethylene triggers its nuclear accumulation. Mutations in PDC lead to an ethylene hyposensitivity that results from the reduction of histone acetylation and transcription activation. Enzymatically active nuclear PDC synthesizes nuclear acetyl CoA for EIN2-C–directed histone acetylation and transcription regulation. These findings uncover a mechanism by which PDC-EIN2 converges the mitochondrial enzyme-mediated nuclear acetyl CoA synthesis with epigenetic and transcriptional regulation for plant hormone response.